Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12682345 | 0.89 | SNCA (0.54) | SNCAKDM4EALDH1A1MAPK1HSD17B10 | |
| SCHEMBL12937562 | 0.88 | SNCA (0.51) | SNCAKDM4EALDH1A1MAPK1HSD17B10 | |
| SCHEMBL12497001 | 0.84 | HSD17B1 (0.49) | KDM4EALDH1A1MAPK1HSD17B10CYP1A2 | |
| SCHEMBL12937546 | 0.81 | SNCA (0.51) | SNCAKDM4EALDH1A1MAPK1HSD17B10 | |
| SCHEMBL12497223 | 0.80 | SNCA (0.55) | SNCAKDM4EALDH1A1MAPK1HSD17B10 | |
| SCHEMBL12682416 | 0.79 | SNCA (0.51) | SNCAKDM4EALDH1A1MAPK1HSD17B10 | |
| SCHEMBL12937504 | 0.77 | HSD17B1 (0.49) | KDM4EALDH1A1MAPK1HSD17B10CYP1A2 | |
| SCHEMBL12682375 | 0.70 | SNCA (1.00) | SNCADYRK1ACYP3A4CYP2C9 | |
| SCHEMBL12937506 | 0.70 | SNCA (0.48) | SNCAKDM4EALDH1A1MAPK1HSD17B10 | |
| SCHEMBL12682373 | 0.70 | PTPN1 (0.59) | SNCAKDM4EALDH1A1MAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180002298-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PROTAMED INC (US) | 2018-01-04 | — | — | US | disclosed |
| US-20170022174-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PROTAMED INC (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170022174-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PROTAMED INC (US) | 2017-01-26 | — | — | US | disclosed |
| US-9334251-B2 | Compounds for the treatment of neurodegenerative diseases | PROTAMED, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334251-B2 | Compounds for the treatment of neurodegenerative diseases | PROTAMED, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150274681-A1 | Compounds for the treatment of Neurodegenerative Diseases | PROTEOTECH INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150274681-A1 | Compounds for the treatment of Neurodegenerative Diseases | PROTEOTECH INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-9085549-B2 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC (US) | 2015-07-21 | — | — | US | disclosed |
| US-9085549-B2 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150011604-A1 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-20150011604-A1 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8865754-B2 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865754-B2 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130338202-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PROTEO TECH, INC (US) | 2013-12-19 | — | — | US | disclosed |
| US-20120251448-A1 | Compounds for Use in the Detection of Neurodegenerative Diseases | AVID RADIOPHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| US-20120251448-A1 | Compounds for Use in the Detection of Neurodegenerative Diseases | AVID RADIOPHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| WO-2012118935-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PROTEOTECH INC (US) | 2012-09-07 | — | — | WO | disclosed |
| WO-2012118935-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PROTEOTECH INC (US) | 2012-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274681-A1 | Compounds for the treatment of Neurodegenerative Diseases | PSEN1, PSEN2, GRN | SNCA 18/4885KDM4E 2532/4885ALDH1A1 4541/4885 |
| US-20180002298-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PSEN1, PSEN2, GRN | SNCA 18/4885KDM4E 2532/4885ALDH1A1 4541/4885 |
| US-20150011604-A1 | Compounds for the treatment of neurodegenerative diseases | SNCA, MAPT, PARK7 | SNCA 1/4885KDM4E 3903/4885ALDH1A1 3487/4885 |
| US-20120251448-A1 | Compounds for Use in the Detection of Neurodegenerative Diseases | SNCA, PARK7, NLN | SNCA 1/4885KDM4E 4630/4885ALDH1A1 2367/4885 |
| US-20170022174-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PSEN1, PSEN2, GRN | SNCA 18/4885KDM4E 2532/4885ALDH1A1 4541/4885 |
| US-20130338202-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, PARK7 | SNCA 1/4885KDM4E 3903/4885ALDH1A1 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.